Combined fiber modifications both to target αvβ 6 and detarget the coxsackievirus-adenovirus receptor improve virus toxicity profiles in vivo but fail to improve antitumoral efficacy relative to adenovirus serotype 5

Human Gene Therapy

Volumn 23, Issue 9, 2012, Pages 960-979

  Coughlan, Lynda ^a   Vallath, Sabari ^b   Gros, Alena ^c   Giménez Alejandre, Marta ^c   Van Rooijen, N ^d   Thomas, Gareth J ^e   Baker, Andrew H ^a   Cascalló, Manel ^c   Alemany, Ramon ^c   Hart, Ian R ^b  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^e UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ALANINE AMINOTRANSFERASE; ALPHAVBETA6 INTEGRIN; ASPARTATE AMINOTRANSFERASE; BLOOD CLOTTING FACTOR 9; COMPLEMENT COMPONENT C4B BINDING PROTEIN; COXSACKIE VIRUS AND ADENOVIRUS RECEPTOR; ENHANCED GREEN FLUORESCENT PROTEIN; GAMMA INTERFERON; INTERLEUKIN 12P70; INTERLEUKIN 6; ONCOLYTIC VIRUS; RANTES; TUMOR NECROSIS FACTOR ALPHA;

ADENOVIRUS 5; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOACCUMULATION; BLOOD SAMPLING; BREAST ADENOCARCINOMA; CANCER GENE THERAPY; CARCINOMA CELL; CHO CELL; CONTROLLED STUDY; COXSACKIE VIRUS; DRUG EFFICACY; DRUG SAFETY; ERYTHROCYTE; EXPRESSION VECTOR; FEMALE; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; KUPFFER CELL; LIVER CELL; MALE; MOUSE; MUTATIONAL ANALYSIS; NONHUMAN; ONCOLYTIC VIROTHERAPY; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN PURIFICATION; PROTEIN TARGETING; RECEPTOR BINDING; SIGNAL TRANSDUCTION; THROMBOCYTOPENIA; TUMOR CELL; TUMOR XENOGRAFT; VIRAL GENE DELIVERY SYSTEM; VIRUS ENTRY; VIRUS GENOME; VIRUS PARTICLE;

ADENOVIRIDAE; ADENOVIRUS E1A PROTEINS; ANIMALS; ANTIGENS, NEOPLASM; BINDING SITES; CHO CELLS; COXSACKIE AND ADENOVIRUS RECEPTOR-LIKE MEMBRANE PROTEIN; CRICETINAE; CRICETULUS; FEMALE; GENE EXPRESSION REGULATION, VIRAL; HEPATOCYTES; HUMANS; INTEGRINS; KUPFFER CELLS; MALE; MICE; MICE, INBRED BALB C; NEOPLASMS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; TRANSDUCTION, GENETIC; VIRAL TROPISM;

ADENOVIRIDAE; COXSACKIEVIRUS;

EID: 84866312862     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2011.218     Document Type: Article

References (74)

1. Ahmed, N., Riley, C., Rice, G.E., et al. (2002). avb6 integrin: A marker for the malignant potential of epithelial ovarian cancer. J. Histochem. Cytochem. 50, 1371-1380.
2. Alba, R., Bradshaw, A.C., Coughlan, L., et al. (2010). Biodistribution and retargeting of FX-binding ablated adenovirus serotype 5 vectors. Blood 116, 2656-2664.
3. Alemany, R., and Curiel, D.T. (2001). CAR-binding ablation does not change biodistribution and toxicity of adenoviral vectors. Gene Ther. 8, 1347-1353. (Pubitemid 32834304)
4. Anders, M., Vieth, M., Rocken, C., et al. (2009). Loss of the coxsackie and adenovirus receptor contributes to gastric cancer progression. Br. J. Cancer 100, 352-359.
5. Bai, X., and Esko, J.D. (1996). An animal cell mutant defective in heparan sulfate hexuronic acid 2-O-sulfation. J. Biol. Chem. 271, 17711-17717. (Pubitemid 26250742)
6. Bame, K.J., and Esko, J.D. (1989). Undersulfated heparan sulfate in a Chinese hamster ovary cell mutant defective in heparan sulfate N-sulfotransferase. J. Biol. Chem. 264, 8059-8065. (Pubitemid 19137289)
7. Bates, R.C., Bellovin, D.I., Brown, C., et al. (2005). Transcriptional activation of integrin b6 during the epithelial-mesenchymal transition defines a novel prognostic indicator of aggressive colon carcinoma. J. Clin. Invest. 115, 339-347. (Pubitemid 40385475)
8. Bergelson, J.M., Krithivas, A., Celi, L., et al. (1998). The murine CAR homolog is a receptor for coxsackie B viruses and adenoviruses. J. Virol. 72, 415-419. (Pubitemid 28048853)
9. Blackhall, F.H., Merry, C.L., Davies, E.J., and Jayson, G.C. (2001). Heparan sulfate proteoglycans and cancer. Br. J. Cancer 85, 1094-1098. (Pubitemid 33052304)
10. Bradshaw, A.C., Parker, A.L., Duffy, M.R., et al. (2010). Requirements for receptor engagement during infection by adenovirus complexed with blood coagulation factor X. PLoS Pathogens 6, e1001142.
11. Breuss, J.M., Gallo, J., Delisser, H.M., et al. (1995). Expression of the b6 integrin subunit in development, neoplasia and tissue repair suggests a role in epithelial remodeling. J. Cell Sci. 108, 2241-2251.
12. Carlisle, R.C., Di, Y., Cerny, A.M., et al. (2009). Human erythrocytes bind and inactivate type 5 adenovirus by presenting coxsackie virus-adenovirus receptor and complement receptor 1. Blood 113, 1909-1918.
13. Cascallo, M., Alonso, M.M., Rojas, J.J., et al. (2007). Systemic toxicity-efficacy profile of ICOVIR-5, a potent and selective oncolytic adenovirus based on the pRB pathway. Mol. Ther. 15, 1607-1615. (Pubitemid 47296599)
14. Cawood, R., Chen, H.H., Carroll, F., et al. (2009). Use of tissuespecific microRNA to control pathology of wild-type adenovirus without attenuation of its ability to kill cancer cells. PLoS Pathogens 5, e1000440.
15. Cichon, G., Boeckh-Herwig, S., Kuemin, D., et al. (2003). Titer determination of Ad5 in blood: A cautionary note. Gene Ther. 10, 1012-1017. (Pubitemid 36722491)
16. Clark, S.E., Warwick, J., Carpenter, R., et al. (2011). Molecular subtyping of DCIS: Heterogeneity of breast cancer reflected in pre-invasive disease. Br. J. Cancer 104, 120-127.
17. Coughlan, L., Vallath, S., Saha, A., et al. (2009). In vivo retargeting of adenovirus type 5 to avb6 integrin results in reduced hepatotoxicity and improved tumor uptake following systemic delivery. J. Virol. 83, 6416-6428.
18. Coughlan, L., Alba, R., Parker, A.L., et al. (2010). Tropismmodification strategies for targeted gene delivery using adenoviral vectors. Viruses 2, 2290-2355.
19. Denby, L., Work, L.M., Graham, D., et al. (2004). Adenoviral serotype 5 vectors pseudotyped with fibers from subgroup D show modified tropism in vitro and in vivo. Hum. Gene Ther. 15, 1054-1064. (Pubitemid 39552287)
20. Di Paolo, N.C., Miao, E.A., Iwakura, Y., et al. (2009a). Virus binding to a plasma membrane receptor triggers interleukin-1a-mediated proinflammatory macrophage response in vivo. Immunity 31, 110-121.
21. Di Paolo, N.C., Van Rooijen, N., and Shayakhmetov, D.M. (2009b). Redundant and synergistic mechanisms control the sequestration of blood-borne adenovirus in the liver. Mol. Ther. 17, 675-684.
22. Doronin, K., Toth, K., Kuppuswamy, M., et al. (2003). Overexpression of the ADP (E3-11.6K) protein increases cell lysis and spread of adenovirus. Virology 305, 378-387. (Pubitemid 36259672)
23. Elayadi, A.N., Samli, K.N., Prudkin, L., et al. (2007). A peptide selected by biopanning identifies the integrin avb6 as a prognostic biomarker for nonsmall cell lung cancer. Cancer Res. 67, 5889-5895. (Pubitemid 46985024)
24. Esko, J.D., Weinke, J.L., Taylor, W.H., et al. (1987). Inhibition of chondroitin and heparan sulfate biosynthesis in Chinese hamster ovary cell mutants defective in galactosyltransferase I. J. Biol. Chem. 262, 12189-12195.
25. Ganesan, L.P., Mohanty, S., Kim, J., et al. (2011). Rapid and efficient clearance of blood-borne virus by liver sinusoidal endothelium. PLoS Pathogens 7, e1002281.
26. Ganesh, S., Gonzalez Edick, M., Idamakanti, N., et al. (2007). Relaxin-expressing, fiber chimeric oncolytic adenovirus prolongs survival of tumor-bearing mice. Cancer Res. 67, 4399-4407. (Pubitemid 46815089)
27. Ganesh, S., Gonzalez-Edick, M., Gibbons, D., et al. (2008). Intratumoral coadministration of hyaluronidase enzyme and oncolytic adenoviruses enhances virus potency in metastatic tumor models. Clin. Cancer Res. 14, 3933-3941.
28. Gimenez-Alejandre, M., Cascallo, M., Bayo-Puxan, N., and Alemany, R. (2008). Coagulation factors determine tumor transduction in vivo. Hum. Gene Ther. 19, 1415-1419.
29. Gros, A., Martinez-Quintanilla, J., Puig, C., et al. (2008). Bioselection of a gain of function mutation that enhances adenovirus 5 release and improves its antitumoral potency. Cancer Res. 68, 8928-8937.
30. Gros, A., Puig, C., Guedan, S., et al. (2010). Verapamil enhances the antitumoral efficacy of oncolytic adenoviruses. Mol. Ther. 18, 903-911.
31. Guedan, S., Gros, A., Cascallo, M., et al. (2008). Syncytia formation affects the yield and cytotoxicity of an adenovirus expressing a fusogenic glycoprotein at a late stage of replication. Gene Ther. 15, 1240-1245.
32. Guedan, S., Rojas, J.J., Gros, A., et al. (2010). Hyaluronidase expression by an oncolytic adenovirus enhances its intratumoral spread and suppresses tumor growth. Mol. Ther. 18, 1275-1283.
33. Guedan, S., Grases, D., Rojas, J.J., et al. (2011). GALV expression enhances the therapeutic efficacy of an oncolytic adenovirus by inducing cell fusion and enhancing virus distribution. Gene Ther. doi: 10.1038/gt.2011.184.
34. Haisma, H.J., Boesjes, M., Beerens, A.M., et al. (2009). Scavenger receptor A: A new route for adenovirus 5. Mol. Pharm. 6, 366-374.
35. Hausner, S.H., Dicara, D., Marik, J., et al. (2007). Use of a peptide derived from foot-and-mouth disease virus for the noninvasive imaging of human cancer: Generation and evaluation of 4-[18F]fluorobenzoyl A20FMDV2 for in vivo imaging of integrin avb6 expression with positron emission tomography. Cancer Res. 67, 7833-7840. (Pubitemid 47281378)
36. Hazelbag, S., Kenter, G.G., Gorter, A., et al. (2007). Overexpression of the avb6 integrin in cervical squamous cell carcinoma is a prognostic factor for decreased survival. J. Pathol. 212, 316-324. (Pubitemid 47010065)
37. Horton, R.M. (1995). PCR-mediated recombination and mutagenesis. SOEing together tailor-made genes. Mol. Biotechnol. 3, 93-99.
38. Jee, Y.S., Lee, S.G., Lee, J.C., et al. (2002). Reduced expression of coxsackievirus and adenovirus receptor (CAR) in tumor tissue compared with normal epithelium in head and neck squamous cell carcinoma patients. Anticancer Res. 22, 2629-2634. (Pubitemid 36069290)
39. Jonsson, M.I., Lenman, A.E., Frangsmyr, L., et al. (2009). Coagulation factors IX and X enhance binding and infection of adenovirus types 5 and 31 in human epithelial cells. J. Virol. 83, 3816-3825.
40. Kalyuzhniy, O., Di Paolo, N.C., Silvestry, M., et al. (2008). Adenovirus serotype 5 hexon is critical for virus infection of hepatocytes in vivo. Proc. Natl. Acad. Sci. U.S.A. 105, 5483-5488. (Pubitemid 351753889)
41. Kirby, I., Davison, E., Beavil, A.J., et al. (1999). Mutations in the DG loop of adenovirus type 5 fiber knob protein abolish highaffinity binding to its cellular receptor CAR. J. Virol. 73, 9508-9514. (Pubitemid 29487106)
42. Kirby, I., Davison, E., Beavil, A.J., et al. (2000). Identification of contact residues and definition of the CAR-binding site of adenovirus type 5 fiber protein. J. Virol. 74, 2804-2813. (Pubitemid 30117592)
43. Koizumi, N., Yamaguchi, T., Kawabata, K., et al. (2007). Fibermodified adenovirus vectors decrease liver toxicity through reduced IL-6 production. J. Immunol. 178, 1767-1773. (Pubitemid 46154648)
44. Koski, A., Rajecki, M., Guse, K., et al. (2009). Systemic adenoviral gene delivery to orthotopic murine breast tumors with ablation of coagulation factors, thrombocytes and Kupffer cells. J. Gene Med. 11, 966-977.
45. Lieber, A., He, C.Y., Meuse, L., et al. (1997). The role of Kupffer cell activation and viral gene expression in early liver toxicity after infusion of recombinant adenovirus vectors. J. Virol. 71, 8798-8807. (Pubitemid 27446464)
46. Liu, Y., Wang, H., Yumul, R., et al. (2009). Transduction of liver metastases after intravenous injection of Ad5/35 or Ad35 vectors with and without factor X-binding protein pretreatment. Hum. Gene Ther. 20, 621-629.
47. Marshall, J.F., Nesbitt, S.A., Helfrich, M.H., et al. (1991). Integrin expression in human melanoma cell lines: Heterogeneity of vitronectin receptor composition and function. Int. J. Cancer 49, 924-931.
48. Martin, K., Brie, A., Saulnier, P., et al. (2003). Simultaneous CARand av integrin-binding ablation fails to reduce Ad5 liver tropism. Mol. Ther. 8, 485-494. (Pubitemid 37161470)
49. Matsumoto, K., Shariat, S.F., Ayala, G.E., et al. (2005). Loss of coxsackie and adenovirus receptor expression is associated with features of aggressive bladder cancer. Urology 66, 441-446. (Pubitemid 41138121)
50. Muruve, D.A., Barnes, M.J., Stillman, I.E., and Libermann, T.A. (1999). Adenoviral gene therapy leads to rapid induction of multiple chemokines and acute neutrophil-dependent hepatic injury in vivo. Hum. Gene Ther. 10, 965-976. (Pubitemid 29195426)
51. Nakayama, M., Both, G.W., Banizs, B., et al. (2006). An adenovirus serotype 5 vector with fibers derived from ovine atadenovirus demonstrates CAR-independent tropism and unique biodistribution in mice. Virology 350, 103-115. (Pubitemid 43870190)
52. Nicol, C.G., Graham, D., Miller, W.H., et al. (2004). Effect of adenovirus serotype 5 fiber and penton modifications on in vivo tropism in rats. Mol. Ther. 10, 344-354. (Pubitemid 39117879)
53. Oberg, D., Yanover, E., Adam, V., et al. (2011). Improved potency and selectivity of an oncolytic E1ACR2 and E1B19K deleted adenoviral mutant in prostate and pancreatic cancers. Clin. Cancer Res. 16, 541-553.
54. Othman, M., Labelle, A., Mazzetti, I., et al. (2007). Adenovirusinduced thrombocytopenia: The role of von Willebrand factor and P-selectin in mediating accelerated platelet clearance. Blood 109, 2832-2839. (Pubitemid 46482078)
55. Parker, A.L., Waddington, S.N., Nicol, C.G., et al. (2006). Multiple vitamin K-dependent coagulation zymogens promote adenovirus-mediated gene delivery to hepatocytes. Blood 108, 2554-2561.
56. Puig-Saus, C., Gros, A., Alemany, R., and Cascallo, M. (2012). Adenovirus i-leader truncation bioselected against cancerassociated fibroblasts to overcome tumor stromal barriers. Mol. Ther. 20, 54-62.
57. Rauen, K.A., Sudilovsky, D., Le, J.L., et al. (2002). Expression of the coxsackie adenovirus receptor in normal prostate and in primary and metastatic prostate carcinoma: Potential relevance to gene therapy. Cancer Res. 62, 3812-3818. (Pubitemid 34728866)
58. Rogee, S., Grellier, E., Bernard, C., et al. (2010). Influence of chimeric human-bovine fibers on adenoviral uptake by liver cells and the antiviral immune response. Gene Ther. 17, 880-891.
59. Saha, A., Ellison, D., Thomas, G.J., et al. (2010). High-resolution in vivo imaging of breast cancer by targeting the pro-invasive integrin avb6. J. Pathol. 222, 52-63.
60. Schiedner, G., Bloch, W., Hertel, S., et al. (2003). A hemodynamic response to intravenous adenovirus vector particles is caused by systemic Kupffer cell-mediated activation of endothelial cells. Hum. Gene Ther. 14, 1631-1641. (Pubitemid 37452873)
61. Seiradake, E., Henaff, D., Wodrich, H., et al. (2009). The cell adhesion molecule "CAR" and sialic acid on human erythrocytes influence adenovirus in vivo biodistribution. PLoS Pathogens 5, e1000277.
62. Shashkova, E.V., Doronin, K., Senac, J.S., and Barry, M.A. (2008). Macrophage depletion combined with anticoagulant therapy increases therapeutic window of systemic treatment with oncolytic adenovirus. Cancer Res. 68, 5896-5904.
63. Shayakhmetov, D.M., Li, Z.Y., Ni, S., and Lieber, A. (2004). Analysis of adenovirus sequestration in the liver, transduction of hepatic cells, and innate toxicity after injection of fibermodified vectors. J. Virol. 78, 5368-5381. (Pubitemid 38581487)
64. Shayakhmetov, D.M., Gaggar, A., Ni, S., et al. (2005). Adenovirus binding to blood factors results in liver cell infection and hepatotoxicity. J. Virol. 79, 7478-7491. (Pubitemid 40756784)
65. Sipos, B., Hahn, D., Carceller, A., et al. (2004). Immunohistochemical screening for b6-integrin subunit expression in adenocarcinomas using a novel monoclonal antibody reveals strong up-regulation in pancreatic ductal adenocarcinomas in vivo and in vitro. Histopathology 45, 226-236. (Pubitemid 39279179)
66. Teicher, B.A. (2006). Tumor models for efficacy determination. Mol. Cancer Ther. 5, 2435-2443. (Pubitemid 44650906)
67. Thomas, G.J., Nystrom, M.L., and Marshall, J.F. (2006). avb6 Integrin in wound healing and cancer of the oral cavity. J. Oral Pathol. Med. 35, 1-10.
68. Van Rooijen, N., and Van Kesteren-Hendrikx, E. (2003). "In vivodepletion of macrophages by liposome-mediated "suicide." Methods Enzymol. 373, 3-16.
69. Vongchan, P., Warda, M., Toyoda, H., et al. (2005). Structural characterization of human liver heparan sulfate. Biochim. Biophys. Acta 1721, 1-8. (Pubitemid 40093506)
70. Waddington, S.N., McVey, J.H., Bhella, D., et al. (2008). Adenovirus serotype 5 hexon mediates liver gene transfer. Cell 132, 397-409. (Pubitemid 351200513)
71. Wallace, J. (2000). Humane endpoints and cancer research. ILAR journal/National Research Council, Institute of Laboratory Animal Resources 41, 87-93.
72. Wernert, N. (1997). The multiple roles of tumour stroma. Virchows Arch. 430, 433-443. (Pubitemid 27322961)
73. Yarnold, J.R., Bamber, J.C., and Gibbs, J. (1986). Tumour growth delay as a clinical endpoint for the measurement of radiation response. Radiother. Oncol. 5, 207-214. (Pubitemid 16125846)
74. Zhang, Y., Chirmule, N., Gao, G.P., et al. (2001). Acute cytokine response to systemic adenoviral vectors in mice is mediated by dendritic cells and macrophages. Mol. Ther. 3, 697-707. (Pubitemid 32509867)